Skip to main content
. 2016 Mar 15;7(14):17290–17300. doi: 10.18632/oncotarget.8039

Figure 2. MMF can be used in combination with many different FDA approved drugs to kill tumor cells.

Figure 2

A. H1975 NSCLC cells (5 vehicle control clones; 5 afatinib resistant clones) were treated with vehicle control; paclitaxel (taxol, 10 nM); [MMF 5 μM + celecoxib 5 μM]; or the drugs in combination for 24h. Twenty four hours after these treatments / irradiation, cells were isolated and processed. Cell viability was assessed using a live/dead assay in a Hermes WiScan microscope at 10X magnification. B. Ovarian cancer cells (OVCAR, Spiky, N1, W2) were treated with vehicle control; paclitaxel (taxol, 10 nM) or docetaxol (10 nM); [MMF 5 μM + celecoxib 5 μM]; or the drugs in combination for 24h. Twenty four hours after these treatments / irradiation, cells were isolated and processed. Cell viability was assessed using a live/dead assay in a Hermes WiScan microscope at 10X magnification. C. Four primary PDX isolates of primary human glioblastoma were treated with vehicle control, MMF (5 μM), FTY720 (100 nM) or the drugs in combination. Twenty four hours after these treatments cells were isolated and processed. Cell viability was assessed using a live/dead assay in a Hermes WiScan microscope at 10X magnification. D. Established mammary carcinoma cell lines (SUM149, SUM190, BT474, BT549) and PDX isolates of human cancer (Spiky - ovarian; ADOR - NSCLC; OSCR-1 - osteosarcoma) were treated with vehicle control, MMF (5 μM), FTY720 (100 nM) or the drugs in combination. Twenty four hours after these treatments cells were isolated and processed. Cell viability was assessed using a live/dead assay in a Hermes WiScan microscope at 10X magnification.